Last reviewed · How we verify
SNP318
At a glance
| Generic name | SNP318 |
|---|---|
| Sponsor | SciNeuro |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients (PHASE2)
- A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SNP318 CI brief — competitive landscape report
- SNP318 updates RSS · CI watch RSS
- SciNeuro portfolio CI